Embed Size (px)
Citation preview
c1
Problem=Opportunity
✓ Reduced efficacy of actual vaccines
✓ Short duration of immunity
✓ No cross-protection against different strains
✓ Biosafety issues
✓ Imperfect costs for end users
Vaccination offers an effective,
inexpensive way to safeguarding the
health and welfare of animals, however
there is still room for innovations
2
VP2 protein is a structural protein of
the Infectious Bursitis virus (IBDV)
what naturally autoassemble
forming Virus-Like Particles
Translation
Assembling
process
x60
VLPs
VP2
protein
VP2 gene
Ch-VLP Platform: Technology Basis
3
Chimeric
VP2
proteins
Ch-VLP Platform: Technology Basis
Chimeric
VP2 gene
Displaying selected epitopes, we can
design chimeric virus like particles
to stimulate the most adequate
response against the target
pathology.
Translation
Chimeric
VLPs
4
Ch-VLP Platform: Technology Basis
5
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50 60
Surv
ival
Rat
e (%
)
Time (Days)
Ch-VLP
Epitope
Control
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
6
Antibodies titer
Ant-VP1 Ant-VP2 Ant-VP3
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
7
• Biosafety: without genetic material it is not able to autoreplicate.
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
8
• High flexibility: Formulation of different Ch-VLPs monocomponents or displaying
different antigens (cellular, humoral or both), consensus sequences, multiple targets…
• Biosafety: without genetic material it is not able to autoreplicate.
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
9
• High flexibility: Formulation of different Ch-VLPs monocomponents or displaying
different antigens (cellular, humoral or both), consensus sequences, multiple targets…
• Biosafety: without genetic material it is not able to autoreplicate.
• Low-cost production system: Already validated in several hosts
• Differentiating Infected from Vaccinated Animals (DIVA).
• High Efficiency: Boosted and durable host immune response.
Ch-VLP Platform: Main Advantages
10
Product Development Roadmap
Preliminary Process
DevelopmentPreliminary
immunogenicity/efficacy
Regulatory Studies Registration
CommercializationIdeaFMD TeStop PRRSV IBDVBVDVPCV2
Prototypes generation
Our Ch-VLPs are ideal vehicles to generate vaccines
against animal pathologies in which protection is
dependent on one or few well-known epitopes
ASFV, Horse Flu, Pet
oncology, etc.
Potential New
Developments
VLPbio Products Portfolio
11
Our products portfolio already contents products against the main
impacting diseases in the veterinary field, targeting a global market
of >1 Billion of Euros.
New vaccines development against the most impacting diseases
- Well recognized and challenging diseases
- Globally distributed diseases
- Competitive landscape
VLPbio Target Market
12
Thank you
VLPbio is a technological company that provide a first-class technology for the development of
new vaccines with differentiating properties to be successfully applied in animal health
The company has a strong and diversified portfolio of products on development for the most
important diseases not properly covered.
To Conclude
13
![Title Authors Affiliations - bioRxiv142 chimeric VLP development are met [13,14,43] which makes this platform an attractive and 143 competitive alternative to previously described](https://img.pdfslide.us/doc/110x75/5fbdde7852e2c97485216b26/title-authors-affiliations-biorxiv-142-chimeric-vlp-development-are-met-131443.jpg)
